What is Barclays's price target for BFAM?

Barclays's latest stated price target for Bright Horizons Family Solutions Inc. (BFAM) is $125, from its action on Feb 28, 2024.

What is Barclays's rating on BFAM?

Barclays rates BFAM Overweight, a bullish rating, as of Feb 28, 2024.

When did Barclays last change its view on BFAM?

On Feb 28, 2024, Barclays upgrades to Overweight from Equal Weight, price target $100 to $125.

Analyst firms · Barclays · BFAM

Barclays BFAM price target and rating history

Bright Horizons Family Solutions Inc. (BFAM) · Consumer Discretionary

Barclays rates Bright Horizons Family Solutions Inc. (BFAM) Overweight with a $125 price target, as of its latest action on Feb 28, 2024. It has published 3 rating actions on BFAM since December 2021, including 1 upgrade and 1 downgrade.

Current rating: Overweight
Price target: $125
Median target, all firms: Too few
Actions on BFAM: 3

Barclays price target on BFAM

Barclays price target on BFAM, each point a stated target, December 2021 to February 2024.

Every Barclays rating on BFAM

Feb 28, 2024
UpgradeBarclays upgrades to Overweight from Equal Weight, price target $100 to $125
Dec 2, 2022
DowngradeBarclays downgrades to Equal Weight from Overweight, price target $75
Dec 13, 2021
ReiterateBarclays cuts its price target to $155 from $180, keeps Overweight

Questions about Barclays and BFAM

What is Barclays's price target for BFAM?: Barclays's latest stated price target for Bright Horizons Family Solutions Inc. (BFAM) is $125, from its action on Feb 28, 2024.
What is Barclays's rating on BFAM?: Barclays rates BFAM Overweight, a bullish rating, as of Feb 28, 2024.
When did Barclays last change its view on BFAM?: On Feb 28, 2024, Barclays upgrades to Overweight from Equal Weight, price target $100 to $125.

More BFAM rating histories

All Barclays ratings BFAM news and filings Every analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.